Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.54 +5.4%	$12.70	$8.04 ▼ $25.88	$367.22M	2.27	416,793 shs	397,041 shs
BNTC Benitec Biopharma	$11.74 -0.1%	$14.10	$7.05 ▼ $17.15	$308.18M	0.37	58,391 shs	147,943 shs
GOSS Gossamer Bio	$1.71 +3.0%	$1.24	$0.66 ▼ $1.79	$388.68M	1.86	1.47 million shs	6.19 million shs
OCX OncoCyte	$3.18 +16.3%	$3.06	$1.92 ▼ $4.75	$90.80M	0.97	57,408 shs	100,514 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-2.28%	-13.12%	-0.16%	+22.03%	-49.37%
BNTC Benitec Biopharma	-5.55%	-15.10%	-25.40%	-14.55%	+12.87%
GOSS Gossamer Bio	+14.48%	+22.06%	+29.69%	+97.62%	+32.80%
OCX OncoCyte	0.00%	0.00%	+16.30%	+11.80%	-3.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	1.9753 of 5 stars	3.6	0.0	0.0	2.1	2.5	0.6
BNTC Benitec Biopharma	1.6031 of 5 stars	3.6	1.0	0.0	2.5	0.8	0.0
GOSS Gossamer Bio	3.7769 of 5 stars	3.5	1.0	4.7	2.7	1.7	0.0
OCX OncoCyte	1.2478 of 5 stars	3.4	0.0	0.0	0.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	298.82% Upside
BNTC Benitec Biopharma	3.20	Buy	$23.83	103.01% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	382.46% Upside
OCX OncoCyte	2.75	Moderate Buy	$6.06	90.94% Upside

Current Analyst Ratings Breakdown

Latest OCX, ARCT, BNTC, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/21/2025	OCX OncoCyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/21/2025	OCX OncoCyte	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $8.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$131.27M	2.80	N/A	N/A	$8.90 per share	1.52
BNTC Benitec Biopharma	$80K	3,852.19	N/A	N/A	$4.68 per share	2.51
GOSS Gossamer Bio	$114.70M	3.39	N/A	N/A	$0.13 per share	13.15
OCX OncoCyte	$3.84M	23.63	N/A	N/A	($0.70) per share	-4.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
OCX OncoCyte	-$60.66M	-$3.53	N/A	N/A	N/A	-1,516.06%	-215.59%	-27.23%	8/6/2025 (Estimated)

Latest OCX, ARCT, BNTC, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
8/6/2025	Q2 2025	OCX OncoCyte	-$0.24	N/A	N/A	N/A	$0.29 million	N/A
8/4/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	N/A	N/A	N/A	$17.64 million	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/12/2025	Q1 2025	OCX OncoCyte	-$0.24	-$0.26	-$0.02	-$0.26	$0.13 million	$2.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	5.28%	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
OCX OncoCyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
BNTC Benitec Biopharma	0.01	14.80	14.80
GOSS Gossamer Bio	6.70	5.71	5.71
OCX OncoCyte	0.20	3.74	3.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
BNTC Benitec Biopharma	52.19%
GOSS Gossamer Bio	81.23%
OCX OncoCyte	55.35%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
BNTC Benitec Biopharma	1.30%
GOSS Gossamer Bio	6.70%
OCX OncoCyte	2.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
OCX OncoCyte	120	28.60 million	28.01 million	No Data

OCX, ARCT, BNTC, and GOSS Headlines

Recent News About These Companies

Oncocyte Exits Irvine, Rebrands as Insight Molecular Diagnostics

June 18, 2025 | ocbj.comO

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

June 17, 2025 | globenewswire.com

Oncocyte Corp. Adjusts Pricing for GraftAssureCore™ Assay to $2,753, Enhancing Market Opportunities and Reimbursement Potential

May 21, 2025 | nasdaq.com

Oncocyte Corporation: Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 20, 2025 | finanznachrichten.de

Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology

May 19, 2025 | finance.yahoo.com

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 19, 2025 | globenewswire.com

Oncocyte Corporation: Oncocyte Reports Q1 2025 Results and Business Progress

May 13, 2025 | finanznachrichten.de

OncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiative

May 13, 2025 | msn.com

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Oncocyte Reports Q1 2025 Results and Business Progress

May 12, 2025 | globenewswire.com

OncoCyte Q1 2025 Earnings Preview

May 11, 2025 | msn.com

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025 | globenewswire.com

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025 | prismmediawire.comP

Why OncoCyte Corporation’s (OCX) Stock Is Up 5.11%

May 7, 2025 | aaii.comA

Best Momentum Stocks to Buy for May 6th

May 6, 2025 | zacks.com

New Strong Buy Stocks for May 6th

May 6, 2025 | zacks.com

Oncocyte Corporation: Oncocyte Provides Positive Update on Clinical Trial Progress

April 30, 2025 | finanznachrichten.de

Oncocyte study links blood test to kidney rejection markers

April 30, 2025 | investing.com

Oncocyte Provides Positive Update on Clinical Trial Progress

April 30, 2025 | globenewswire.com

Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity

April 29, 2025 | taiwannews.com.twT

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCX, ARCT, BNTC, and GOSS Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$13.54 +0.69 (+5.37%)

Closing price 04:00 PM Eastern

Extended Trading

$13.68 +0.14 (+1.00%)

As of 06:46 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Benitec Biopharma NASDAQ:BNTC

$11.74 -0.01 (-0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$11.71 -0.03 (-0.26%)

As of 06:25 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Gossamer Bio NASDAQ:GOSS

$1.71 +0.05 (+3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 -0.01 (-0.58%)

As of 06:44 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

OncoCyte NASDAQ:OCX

$3.18 +0.45 (+16.30%)

Closing price 06/17/2025

Extended Trading

$3.18 0.00 (0.00%)

As of 06/17/2025 07:21 PM Eastern

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time